[Use of zoledromic acid on pain control in stages M1b of prostate cancer].

OBJECTIVES

To probe the use of Zoledromic acid in the control of the pain due to bone methastasis of a prostate cancer.

MATERIAL AND METHOD

We included in our study 37 consecutive patients diagnosed of prostate cancer who developed bone methastasis during 2005 and 2006 to whom we gave a 4 mg dose of Zoledromic acid during a mean time of 10.24 months.

RESULTS

We observed a complete control of the pain in 8 of the 20 patients, and partially in 6 of those patients. We did not evaluate any adverse reaction due to this treatment.

CONCLUSIONS

We still yet to know whether the administration of this treatment in the early stages of the prostate cancer could prevent or retard the appearance of bone methastasis.